Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen

scientific article published on 29 January 2020

Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen is …
instance of (P31):
case reportQ2782326
scholarly articleQ13442814

External links are
P356DOI10.1007/S13300-020-00765-6
P932PMC publication ID7048887
P698PubMed publication ID31994009

P50authorMasakazu TakeuchiQ91407325
Tomonori OuraQ91802505
P2093author name stringYukiko Onishi
Hitoshi Ishii
P2860cites workβ cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East AsiansQ35572729
Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K StudyQ35754150
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusQ37141727
Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.Q37295993
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III studyQ37295997
Real-life glycemic control in patients with type 2 diabetes treated with insulin therapy: A prospective, longitudinal cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT 9]).Q38685102
Attitudes of patients and physicians to insulin therapy in Japan: an analysis of the Global Attitude of Patients and Physicians in Insulin Therapy studyQ39185926
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion proteinQ43054066
Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trialQ49576747
A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trialQ86505712
A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 DiabetesQ90117073
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?Q91198085
Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled StudyQ91407328
P433issue3
P921main subjecttype 2 diabetesQ3025883
P304page(s)735-745
P577publication date2020-01-29
P1433published inDiabetes TherapyQ26853803
P1476titleEfficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
P478volume11

Search more.